利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

72 条记录 (耗时 0.027 秒)

    COMPOSITIONS COMPRISING OMEGA-3 FATTY ACIDS AND VITAMIN D FOR PSORIASIS, AND METHODS AND USES THEREOF
    2.
    发明公开
    COMPOSITIONS COMPRISING OMEGA-3 FATTY ACIDS AND VITAMIN D FOR PSORIASIS, AND METHODS AND USES THEREOF 审中-公开
    与ω-3脂肪酸和维生素D的组合物治疗牛皮癣和方法及其用途

    公开(公告)号：EP2833881A1

    公开(公告)日：2015-02-11

    申请号：EP13730321.0

    申请日：2013-03-15

    申请人： Pronova BioPharma Norge AS

    发明人： FRASER, David A. ,  GARRAS, Alexis

    IPC分类号： A61K31/202 ,  A61P17/06 ,  A61K31/593

    CPC分类号： A61K31/593 ,  A23L33/12 ,  A23L33/155 ,  A23V2002/00 ,  A61K31/202

    摘要： The present disclosure relates to pharmaceutical compositions comprising omega-3 fatty acids and vitamin D for use in at least one of preventing and treating psoriasis, and to food supplement, dietary supplement, nutritional supplement, over-the-counter (OTC) supplement, medical food, or pharmaceutical grade supplement compositions comprising omega-3 fatty acids and vitamin D for use in improving at least one parameter associated with psoriasis.

    摘要翻译： 本公开涉及药物组合物包含ω-3脂肪酸和维生素D用于预防和治疗牛皮癣中的至少一个，以及食品补充剂，膳食补充剂，营养补充剂，过度的非处方（OTC）补充物，医学 食品，或药物级补充组合物包含ω-3脂肪酸和维生素D用于改善与牛皮癣有关的至少一个参数。

    METHODS OF TREATMENT USING LIPID COMPOUNDS
    4.
    发明公开
    METHODS OF TREATMENT USING LIPID COMPOUNDS 有权
    治疗与脂类化合物方法

    公开(公告)号：EP2635270A1

    公开(公告)日：2013-09-11

    申请号：EP11837647.4

    申请日：2011-11-03

    申请人： Pronova BioPharma Norge AS

    发明人： HOVLAND, Ragnar ,  SKJÆRET, Tore ,  FRASER, David A.

    IPC分类号： A61K31/19 ,  A61P3/04 ,  A61P3/06 ,  A61P3/10 ,  A61P9/10 ,  C07C57/03

    CPC分类号： C07C69/734 ,  A61K31/19 ,  A61K31/355 ,  C07C59/60 ,  C07D263/26 ,  A61K2300/00

    摘要： Methods are disclosed to treat or prevent at least one disease or condition in a subject in need thereof comprising administering a compound of Formula (I): (I) or a pharmaceutically acceptable salt, or ester thereof, wherein R
    1 and R
    2 are independently chosen from a hydrogen atom or linear, branched, and/or cyclic C
    1 -C
    6 alkyl groups, with the proviso that R
    1 and R
    2 are not both hydrogen or a pharmaceutically acceptable salt or ester thereof. Such diseases or conditions may relate to coronary heart disease (CHD), for example atherosclerosis; metabolic syndrome/insulin resistance; and/or a dyslipidemic condition such as hypertriglyceridemia (HTG), elevated LDL- cholesterol, elevated total-cholesterol, elevated Apo B and low HDL-cholesterol. The present disclosure further provides for a method of reducing atherosclerosis development. Pharmaceutical compositions comprising a compound of Formula (I) are also disclosed.